| Literature DB >> 31576761 |
Sinan Bilginer1, Halise Inci Gul1, Feyza Sena Erdal1, Hiroshi Sakagami2, Serkan Levent3, Ilhami Gulcin4, Claudiu T Supuran5.
Abstract
In this study, new chalcone compounds having theEntities:
Keywords: Anticancer; benzoxazolone; carbonic anhydrase; chalcone; cytotoxic
Mesh:
Substances:
Year: 2019 PMID: 31576761 PMCID: PMC6781194 DOI: 10.1080/14756366.2019.1670657
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Scheme 1.Synthesis of the compounds 1–8. Ar: Phenyl (1); 4-methylphenyl (2); 4-Methoxyphenyl (3); 4-trifluoromethylphenyl (4); 3-hyrdoxyphenyl (5); 4-isopropylphenyl (6); 4-dimethylaminophenyl (7); 4-benzyloxyphenyl (8).
Figure 1.The details of 1H-NMR spectra of compound 2 as represantative 1H-NMR. δ (ppm) Ha: 8.05 (dd, 1H, JHa-Hb: 8.1 Hz, JHa-Hc: 1.5 Hz), Hb: 7.22 (d, 1H, JHa-Hb: 8.1 Hz), Hc: 8.08 (d, 1H, JHa-Hc: 1.5 Hz), Hd: 7.79 (d, 2H, JHd-He: 8.0 Hz), He: 7.27 (d, 2H, JHd-He: 8.0 Hz), Hα: 7.93 (d, 1H, JHα-Hβ: 15.5 Hz), Hβ: 7.70 (d, 1H, JHα-Hβ: 15.5 Hz) CH3 protons: 2.35 (s, 3H).
Cytotoxic activities of the compounds 1–8 towards human OSCC cell lines and human oral normal cells
| CC50(μM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| OSCC | Human normal oral cells | ||||||||
| HSC-2 | SD | HGF | SD | HPLF | SD | Mean | TS | PSE | |
| Compounds | (A) | (B) | (B/A) | (B/A2)×100 | |||||
| 22.1 | 1.2 | 71.0 | 9.5 | 83.3 | 14.0 | 77.2 | 3.5 | 16 | |
| 10.1 | 0.4 | 87.7 | 18.5 | 105.3 | 3.1 | 96.5 | 9.5 | 94 | |
| 14.5 | 2.9 | 88.3 | 17.9 | 84.0 | 0.0 | 86.2 | 5.9 | 41 | |
| 4.0 | 0.6 | 24.7 | 0.6 | 26.3 | 0.5 | 25.5 | 6.4 | 159 | |
| 6.9 | 0.5 | 55.4 | 19.7 | 50.3 | 3.5 | 52.9 | 7.7 | 111 | |
| 10.1 | 0.5 | 53.0 | 5.3 | 76.0 | 7.0 | 64.5 | 6.4 | 64 | |
| 30.2 | 3.2 | 76.3 | 9.3 | 70.0 | 2.0 | 73.2 | 2.4 | 8 | |
| 11.9 | 0.2 | 98.0 | 50.2 | 32.7 | 1.5 | 65.3 | 5.5 | 46 | |
| 5-FU | 37.7 | 0.0 | >1000 | 0.0 | >1000 | 0.0 | >1000 | >28.3 | 80.7 |
| DXR | 0.5 | 0.1 | 0.7 | 0.0 | >10 | 0.0 | >5.3 | >10.4 | >2030 |
5-Fluorouracil (5-FU) and Doxorubicin (DXR) were used as reference drugs.
SD: standard deviation.
Inhibitory effects of the compounds 1–8 on hCA I and hCA II isoenzymes.
| IC50 (µM) | K | |||||
|---|---|---|---|---|---|---|
| Compounds | hCA I | hCA II | hCA I | hCA II | ||
| 58.72 | 0.9613 | 40.53 | 0.9392 | 70.58 ± 6.67 | 36.16 ± 13.35 | |
| 33.00 | 0.9546 | 45.59 | 0.9786 | 38.80 ± 1.93 | 32.12 ± 6.60 | |
| 47.46 | 0.9406 | 48.13 | 0.9854 | 30.49 ± 11.26 | 36.20 ± 10.26 | |
| 29.74 | 0.9397 | 45.0 | 0.9778 | 30.75 ± 3.49 | 19.2 ± 2.19 | |
| 69.57 | 0.9375 | 48.46 | 0.9509 | 63.04 ± 15.45 | 35.20 ± 8.36 | |
| 52.11 | 0.9496 | 30.13 | 0.9356 | 37.05 ± 7.77 | 33.29 ± 6.15 | |
| 40.29 | 0.9533 | 29.74 | 0.9538 | 52.25 ± 9.97 | 10.85 ± 2.14 | |
| 57.75 | 0.9509 | 18.14 | 0.9397 | 28.37 ± 6.63 | 37.96 ± 2.36 | |
| AZA | 16.58 | 0.9887 | 8.37 | 0.9825 | 30.18 ± 7.77 | 4.41 ± 0.55 |
Acetazolamide (AZA) was used as a standard inhibitor for both hCA I and II isoenzymes. r2: is a statistical measure of how close the data are to the fitted regression line. It is also known as the coefficient of determination, or the coefficient of multiple determinations for multiple regressions.